Robert Arthur Harrington Sells 253 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Robert Arthur Harrington sold 253 shares of Cytokinetics stock in a transaction on Friday, July 5th. The shares were sold at an average price of $54.61, for a total transaction of $13,816.33. Following the sale, the director now directly owns 15,516 shares of the company’s stock, valued at approximately $847,328.76. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Robert Arthur Harrington also recently made the following trade(s):

• On Monday, June 3rd, Robert Arthur Harrington sold 1,580 shares of Cytokinetics stock. The shares were sold at an average price of $48.64, for a total transaction of $76,851.20.

Cytokinetics Trading Up 0.1 %

Shares of Cytokinetics stock opened at $54.93 on Thursday. The stock has a market capitalization of $5.76 billion, a price-to-earnings ratio of -10.17 and a beta of 0.75. Cytokinetics, Incorporated has a 1-year low of $25.98 and a 1-year high of $110.25. The firm’s 50-day moving average price is $55.25 and its two-hundred day moving average price is $67.96.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.17). The business had revenue of $0.84 million for the quarter, compared to analysts’ expectations of $0.91 million. The company’s revenue was down 81.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.38) earnings per share. As a group, equities research analysts predict that Cytokinetics, Incorporated will post -4.5 EPS for the current year.

Institutional Trading of Cytokinetics

Large investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp grew its stake in Cytokinetics by 94.1% during the first quarter. Fifth Third Bancorp now owns 656 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 318 shares during the last quarter. GAMMA Investing LLC acquired a new position in shares of Cytokinetics during the fourth quarter worth approximately $80,000. EntryPoint Capital LLC acquired a new position in shares of Cytokinetics during the first quarter worth approximately $74,000. Bessemer Group Inc. lifted its position in shares of Cytokinetics by 25,100.0% during the first quarter. Bessemer Group Inc. now owns 1,260 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 1,255 shares in the last quarter. Finally, Sage Rhino Capital LLC acquired a new position in shares of Cytokinetics during the fourth quarter worth approximately $204,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Raymond James decreased their target price on shares of Cytokinetics from $92.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, May 23rd. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Cytokinetics in a report on Monday, June 17th. B. Riley cut their price target on shares of Cytokinetics from $122.00 to $92.00 and set a “buy” rating on the stock in a report on Tuesday, June 4th. JMP Securities cut their price target on shares of Cytokinetics from $106.00 to $78.00 and set a “market outperform” rating on the stock in a report on Tuesday, May 28th. Finally, Oppenheimer cut their price target on shares of Cytokinetics from $107.00 to $106.00 and set an “outperform” rating on the stock in a report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $77.06.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.